Lipids and lipid lowering: current management with statins and PCSK9 inhibitors-Reference-Cited by-同舟云学术

Lipids and lipid lowering: current management with statins and PCSK9 inhibitors

Published:2018-04-07 Issue:14 Volume:39 Page:1117-1120
ISSN:0195-668X
Container-title:European Heart Journal
language:en
Short-container-title:

Author:

Lüscher Thomas F¹

Affiliation:

1. Editorial Office, Zurich Heart House, 8032 Zurich, Center for Molecular Cardiology, Schlieren Campus, University of Zurich, Switzerland and Royal Brompton and Harefield Hospital Trust and Imperial College, London, SW3 6NP, UK

Publisher

Oxford University Press (OUP)

Subject

Cardiology and Cardiovascular Medicine

Link

http://academic.oup.com/eurheartj/article-pdf/39/14/1117/24554114/ehy187.pdf

Reference29 articles.

1. Über experimentelle Cholesterinsteatose und ihre Bedeutung für die Entsthung einiger pathologischer Prozesse;Anitschkow;Zentralblatt für Allgemeine Pathologie und Pathologische Anatomie,1913

2. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study;Castelli;JAMA,1986

3. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S);Lancet,1994

4. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel;Ference;Eur Heart J,2017

5. 2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia;Landmesser;Eur Heart J,2018

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A short review of proprotein convertase subtilisin/kexin type 9 inhibitors;Reviews in Cardiovascular Medicine;2019